Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers Squibb Subscribes to LifeSpan s GPCR Database

NEW YORK, Feb 7 – Bristol-Myers Squibb has agreed to subscribe to LifeSpan Biosciences’ G Coupled-Protein Receptors database, the companies said Wednesday.

The database provides expression and localization information for GPCRs, a large class of cell-surface molecules that act as cellular receptors for many biologically active compounds and pharmaceuticals.

Bristol-Myers Squibb joins fellow pharmaceutical companies Pfizer, Novartis, and Merck as a subscriber to the database.

“This agreement provides Bristol-Myers Squibb with access to human gene expression data in tissues important in health and disease, and will aid our efforts in validating new drug targets,” said Mark Cockett, executive director, functional genomics of Bristol-Myers Squibb in a statement.

Subscribers to the GPCR database receive early access to localization data on GPCR targets, as well as continuous updates to the database.

“LifeSpan’s molecular pathology approach provides the next generation of information that allows pharmaceutical companies to prioritize the best potential drug targets from among the many candidates identified by high-throughput sequencing and gene chips,” said Lifespan CEO Joseph Brown.

LifeSpan was not immediately available for comment. 

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.